MORPHINE SULFATE INJECTION SDZ 10 MG
MORPHINE SULFATE : 10 MG · DIN 02382997 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is MORPHINE SULFATE INJECTION SDZ?
MORPHINE SULFATE INJECTION SDZ 10 MG contains MORPHINE SULFATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02382997, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 18-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MORPHINE SULFATE INJECTION SDZ used for?
Relief of moderate to severe pain in adults. Not indicated as an as-needed (prn) analgesic.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02382997 |
|---|---|
| Brand name | MORPHINE SULFATE INJECTION SDZ |
| Generic / active ingredient | MORPHINE SULFATE : 10 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA01 MORPHINE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Oct-2012 |
| Original market date | 2012-10-18 00:00:00 |
How is it administered?
Administered by slow intravenous, intramuscular, or subcutaneous injection. Not for prn use. Dosage must be individualized. Start at low end for elderly.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store securely to avoid theft or misuse. Do not use unless solution is clear. (Specific temperature range not provided in excerpt).
How is it supplied?
Not explicitly detailed in provided text beyond 'package' and 'solution' mentions; refer to DOSAGE FORMS, COMPOSITION AND PACKAGING section.
Contraindications
Hypersensitivity to morphine; GI obstruction/ileus; surgical abdomen; mild pain; asthma/COPD; respiratory depression; acute alcoholism; convulsive disorders; head injury; MAO inhibitors.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and fatal respiratory depression. Concomitant use with benzodiazepines or alcohol may result in coma or death. Risk of hypotension and head injury complications.
Is MORPHINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AA01 MORPHINE. 56 of 172 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOLORAL SIROP | 1 MG | SYRUP | LABORATOIRE ATLAS INC | MARKETED | DIN 00614491 |
| DOLORAL SIROP | 5 MG | SYRUP | LABORATOIRE ATLAS INC | MARKETED | DIN 00614505 |
| KADIAN | 10 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02242163 |
| KADIAN | 100 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02184451 |
| KADIAN | 20 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02184435 |
| KADIAN | 200 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02559722 |
| KADIAN | 50 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02184443 |
| M-EDIAT | 10 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320428 |
| M-EDIAT | 20 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320436 |
| M-EDIAT | 30 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | DIN 02320444 |
Who else supplies MORPHINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MORPHINE appears in 167 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.